This study is testing a drug called Loncastuximab Tesirine (Lonca) in people with large B-cell lymphoma (LBCL) that has come back or not responded to previous treatments, specifically after CAR T-cell therapy. The goal is to see if Lonca can help patients who have had some improvement (called "partial response" or PR) after CAR T-cell therapy to achieve a complete response. Researchers will also look at the safety of Lonca and any side effects it might cause. You may be able to join if you are 18 or older and have relapsed or refractory LBCL, primary mediastinal B-cell lymphoma, transformed indolent B-cell lymphomas, or high-grade B-cell lymphoma. The study aims to enroll 30 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 30 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary goal of the study is to measure conversion to complete response through study completion and/or an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.